Nasal High Frequency Oscillation Ventilation(NHFOV) for Respiratory Distress Syndrome

Overview

In very preterm infants with severe respiratory distress syndrome(RDS), invasive ventilation(IV) , besides nasal continuous positive airway pressure (NCPAP) and early/selective pulmonary surfactant administration, is one key cornerstone to reduce neonatal mortality. However, IV is related to increased risks of bronchopulmonary dysplasia (BPD) and abnormal developmental outcomes in the survival.Weaning from IV is therefore a key procedure to reducing these risks above, and if extubation does not success, repeated intubation and/or prolonged duration of IV will result in increased medical burden and intubation-associated complications and death. How to minimize the need for endotracheal ventilation and subsequent complications constitutes a challenge for neonatologists.

Full Title of Study: “Nasal High Frequency Oscillation Ventilation(NHFOV) vs. Nasal Continuous Positive Airway Pressure(NCPAP) as Post-extubation Respiratory Support in Preterm Infants With Respiratory Distress Syndrome:a Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Investigator, Outcomes Assessor)
  • Study Primary Completion Date: June 30, 2018

Detailed Description

Early weaning from invasive ventilation and avoiding re-intubation remains a focus. Nowadays, early use of noninvasive respiratory support strategies has been suggested to be the most effective pathway to reduce those risks. NCPAP is a widely used way of noninvasive ventilation strategies in preterm infants. However, there is only 60% success rate in avoiding intubation. Supplying with the combined advantages of HFOV and NCPAP with high CO2 removal, no need for synchronisation, less volume/barotraumas, non-invasion and increased functional residual capacity, nasal high frequency oscillation ventilation (NHFOV) is considered as a strengthened version of NCPAP. Thus, NHFOV may be more effective as post-extubation respiratory support to avoid re-intubation and subsequent complications/sequelae comparing with NCPAP in preterm infants. To date, NHFOV was used increasingly in neonatal intensive care unit (NICU) around the world due to its convenient operation and no consideration of synchronisation, and several small studies have reported the beneficial effects of NHFOV in preterm infants. However, there were rare randomized controlled studies compared NHFOV with NCPAP as post-extubation respiratory support strategies in preterm infants. The purpose of the present study was to compare NHFOV with NCPAP as post-extubation respiratory support on the need for endotracheal ventilation and subsequent complications in preterm infants.

Interventions

  • Device: NHFOV
    • NHFOV is used as the noninvasive mode after extubation
  • Device: NCPAP
    • NCPAP is used as the noninvasive mode after extubation

Arms, Groups and Cohorts

  • Experimental: NHFOV
    • NHFOV is used as the supporting mode after extubation
  • Active Comparator: NCPAP
    • NCPAP is used as the supporting mode after extubation

Clinical Trial Outcome Measures

Primary Measures

  • intubation rate
    • Time Frame: 3 days
    • the baby was re-intubated due to respiratory failure
  • total time of hospitalization
    • Time Frame: 100 days
    • the duration of baby in hospital
  • bronchopulmonary dysplasia(BPD)
    • Time Frame: at 28 days after birth or 36 weeks’gestational age or at discharge
    • bronchopulmonary dysplasia was diagnosed after extubation BPD was defined according to the National Institutes of Health consensus definition

Secondary Measures

  • airleaks
    • Time Frame: 3 days
    • airleaks was diagnosed after extubation
  • Retinopathy of prematurity
    • Time Frame: 100 days
    • Retinopathy of prematurity was diagnosed after extubation
  • Neonatal necrotizing enterocolitis
    • Time Frame: 3 days
    • Neonatal necrotizing enterocolitis was diagnosed after extubation
  • Intraventricular hemorrhage
    • Time Frame: 3 days
    • Intraventricular hemorrhage was diagnosed after extubation
  • mortality rate
    • Time Frame: 100 days
    • the baby died in hospital
  • patent ductus arteriosus (PDA)
    • Time Frame: 100 days
    • patent ductus arteriosus (PDA) was diagnosed

Participating in This Clinical Trial

Inclusion Criteria

  • The gestational age was less than 37 weeks; – These neonates were diagnosed with RDS and supported by invasive ventilation with synchronized intermittent mandatory ventilation (SIMV. The diagnosis of RDS was based on clinical manifestations and chest X-ray findings. The clinical signs and symptoms of RDS were respiratory distress, tachypnea, nasal flaring, groan, and cyanosis after birth. The typical X-ray picture of RDS showed a grain shadow, air bronchogram or white lung; – The neonates were ready to be extubated for the first time and subsequent noninvasive ventilation. Exclusion Criteria:

  • parents' decision not to participate; – major congenital anomalies; – died or left the NICU within 24 hour. Eligibility criteria for extubation: Besides the improved symptoms, X-rays and sufficient spontaneous breathing efforts, the eligibility criteria for extubation were peak inspiratory pressure (PIP) of 15-20 cm H2O, positive end expiratory pressure (PEEP) of 4-6 cm H2O, respiratory rate of 15 to 30, FiO2 from 0.21 to 0.30, hematocrit more than 35%. and arterialized capillary blood gas analysis need to meet the following criteria: pH>7.20, PaCO2<=55 mmHg.

Gender Eligibility: All

Minimum Age: 30 Minutes

Maximum Age: 1 Month

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ma Juan, Director – Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
  • Overall Official(s)
    • Shi Yuan, PhD,MD, Study Director, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.